Re: Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5

Samir S. Taneja

    Research output: Contribution to journalComment/debatepeer-review

    Original languageEnglish (US)
    Number of pages1
    JournalJournal of Urology
    Volume194
    Issue number4
    DOIs
    StatePublished - Oct 1 2015

    ASJC Scopus subject areas

    • Urology

    Cite this